Pacemaker Physiological Sensor Integration Patent Landscape
Cardiac Pacemakers Inc commands the largest share among the top filers, with the top five applicants accounting for more than half of the hundred largest filers’ combined output. Annual volume peaked around 2020 and has since eased, placing the field in a decline stage where established players hold entrenched positions and new entrants are making selective, targeted bets.
Cardiac Pacemakers Inc leads a concentrated field dominated by established device makers
Cardiac Pacemakers Inc ranks first with 100 patent records, nearly double the second-ranked Pacesetter Inc at 56 and third-ranked Medtronic Inc at 54, establishing a clear lead tier among the top applicants.
The top five filers — Cardiac Pacemakers Inc, Pacesetter Inc, Medtronic Inc, MED EL Elektromedizinische Geraete GmbH, and Intermedics Inc — together account for 57% of the hundred largest filers’ combined total, indicating moderate-to-high concentration with a meaningful gap between the first tier and the rest of the field.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | Cardiac Pacemakers Inc | 100 | |
| 2 | Pacesetter Inc | 56 | |
| 3 | Medtronic Inc | 54 | |
| 4 | MED EL Elektromedizinische Geraete GmbH | 28 | |
| 5 | Intermedics Inc | 21 | |
| 6 | BIOTRONIK SE & CO KG | 19 | |
| 7 | Sigmasense LLC | 17 | |
| 8 | Ceryx Medical Ltd | 14 | |
| 9 | Nanostim Inc | 13 | |
| 10 | St. Jude Medical AB | 9 |
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 11 | MAYO FOUNDATION FOR MEDICAL EDUCATION & RESEARCH | 8 | |
| 12 | Remon Medical Technologies | 8 | |
| 13 | Inspire Medical Systems Inc | 7 | |
| 14 | Abiomed Inc | 6 | |
| 15 | EBR Systems Inc | 5 | |
| 16 | Vital Connect Inc | 5 | |
| 17 | Impulse Dynamics NV | 5 | |
| 18 | Board of Trustees of the Leland Stanford Junior University | 5 | |
| 19 | Julio C. Spinelli | 3 | |
| 20 | Tamara Colette Baynham | 3 |
This concentration reflects the capital-intensive nature of implantable cardiac device development and long regulatory timelines; incumbents have built layered patent portfolios that raise the barrier for challengers seeking broad cross-system coverage.
Filing counts for the most recent 18–24 months are subject to publication lag and likely understate true activity; conclusions about very recent trends should be treated as provisional. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
Volume peaked in 2020 and has eased; electrotherapy dominates the technology mix
The annual filing trend reveals a field that expanded through the late 2010s, crested near 2020, and has since moderated. The technology composition shows a commanding concentration in electrotherapy and radiation therapy (A61N), with diagnostics and surgery (A61B) as the main secondary branch.
Annual filing trend
Filings climbed from 13 records in 2017, dipped in 2018, then rose to a peak of 17 in 2020 before declining to single digits by 2023–2025. Counts for 2024 and 2025 are almost certainly understated due to publication lag and should not be read as a continuing decline.
↗ Hover for values · click a bar to ask EurekaTechnology composition
A61N (Electrotherapy and radiation therapy) accounts for the largest share of patent records by a wide margin, followed by A61B (Diagnosis and surgery). Smaller branches — including A61M (devices for body fluids), H04B (transmission), and signal-measurement classes G01H and G01P — represent thin but technically coherent adjacent areas.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Rate responsive leadless cardiac pacemaker
A leadless cardiac pacemaker comprises a housing, a plurality of electrodes coupled to an outer surface of the housing, and a pulse delivery system hermetically contained within the housing and electrically coupled to the electrode plurality, the pulse delivery system configured for sourcing energy internal to the housing, generating and delivering… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Method and apparatus to automatically optimize the… | 689 |
| 2 | Cardiac stimulating apparatus and method for heart… | 573 |
| 3 | Apparatus and methods using acoustic telemetry for… | 532 |
| 4 | Method for measuring baroreflex sensitivity and th… | 521 |
| 5 | Rate adaptive cardiac rhythm management device con… | 499 |
| 6 | Cardiac pacemaker with automatic response optimiza… | 496 |
| 7 | Method of pacing a heart using implantable device | 370 |
| 8 | Method and apparatus for rate-responsive cardiac p… | 367 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
What the competitive structure means for R&D investment decisions
The combination of a mature lifecycle, high incumbent concentration, and selective new-entrant activity shapes where incremental versus disruptive investment is likely to pay off.
Field in decline phase after 2020 peak
The lifecycle stage is classified as Decline, with annual filing volume easing back from its 2020 peak. For R&D teams, this signals that core electrotherapy-sensor integration claims are largely staked; incremental work in the dominant A61N space faces a crowded prior-art landscape. Investment logic shifts toward differentiated sensor modalities or system-level integration rather than foundational stimulation-sensing claims.
Lifecycle: DeclineTop five hold majority share among the largest filers
With the top five applicants controlling 57% of the hundred largest filers’ combined output and a near-2× gap between the leader and the second-ranked applicant, the field is dominated by legacy device companies. Smaller entrants such as Sigmasense LLC (17 patent records) and Ceryx Medical Ltd (14) occupy narrow niches rather than broad platform positions. New entrants face a concentrated prior-art wall in core A61N claims.
Concentration: HighCeryx Medical and University of Bath are the active co-filers
The only identified co-applicant pairing in the evidence is Ceryx Medical Ltd and the University of Bath, with 10 jointly filed records. This industry–academia collaboration in a niche implant company suggests targeted research on specific sensor or stimulation mechanisms. No other multi-party collaborations are identified in the evidence, indicating that cross-company alliances remain limited in this space.
Co-filing: LimitedUS-anchored, with European and PCT secondary routes
The United States is the primary filing jurisdiction with 201 patent records, followed by Europe (EPO) at 104 and WIPO (PCT) at 52. Secondary national filings in Australia, Canada, Germany, the UK, India, and Japan indicate that leading applicants pursue international coverage, but the US–EPO–PCT corridor handles the vast majority of global protection activity.
Lead office: United StatesGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
| Applicant | Collaborator | Co-filings |
|---|---|---|
| Ceryx Medical Ltd | University of Bath | 10 |
Co-filing pairs, ranked by the number of jointly-filed patent families.
Cardiac Pacemakers Inc and Medtronic lead on different sensor technology axes
The top two players share dominance in core electrotherapy claims but diverge meaningfully in secondary sensor emphasis, with Medtronic extending into motion and vibration measurement while Cardiac Pacemakers Inc concentrates on diagnostic sensing.
Cardiac Pacemakers Inc
Cardiac Pacemakers Inc holds 100 patent records — the largest count among ranked applicants — with its technology focus concentrated in A61N 1 (electrotherapy) and A61B 5 (diagnostic sensing). The applicant momentum trend is listed as new entrant in the recent window, suggesting recent filing activity is modest relative to its accumulated portfolio, consistent with the field’s overall post-peak pattern.
patent records: 100Medtronic Inc
Medtronic Inc holds 54 patent records and is notable for extending beyond core electrotherapy (A61N 1) into G01H 11 (measuring vibrations and sound) and G01P 1 (velocity and acceleration), reflecting a sensor-diversification strategy around motion-based physiological inputs. Its momentum trend is listed as new entrant in the recent window, indicating recent filings are a fresh addition relative to its prior activity.
patent records: 54| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| Cardiac Pacemakers Inc | 3 | ▲ new entrant |
| Medtronic Inc | 4 | ▲ new entrant |
| Biotronik SE & Co KG | 5 | ▲ new entrant |
| Sigmasense LLC | 9 | ▲ new entrant |
| Ceryx Medical Ltd | 3 | ▼ -73% |
| University of Bath | 2 | ▲ new entrant |
Under-served adjacent branches worth monitoring
Several IPC classes appear at low share within the corpus, representing areas where patent density is thin relative to technical relevance. These are observations of relative sparsity — not validated commercial opportunities — but two have plausible technical and entry rationale worth noting.
G01H / G01P — Motion and vibration sensing
G01H (measuring vibrations and sound) and G01P (velocity and acceleration) each account for only 7 patent records, yet Medtronic has already demonstrated technical investment in both sub-classes. Accelerometer- and seismocardiography-based rate-adaptive pacing is a well-understood mechanism, making this a technically credible entry path. The sparse patent density means freedom-to-operate may be broader here than in the dominant A61N corridor, and entry could be pursued via sensor-specific claims rather than full-system pacemaker claims.
Search this in Eureka →H04B — Implant wireless transmission for sensor data
H04B (transmission, general) holds 17 patent records, representing only about 3% of the branch distribution, despite wireless telemetry being a recognized enabler of closed-loop sensor-driven pacing. Nanostim Inc’s portfolio shows particular emphasis here (15 patent records in H04B 13), but the overall branch remains lightly contested. Companies with strengths in low-power RF or ultrasonic body-area communication could potentially file in this branch without directly competing against the dense A61N prior-art core.
Search this in Eureka →Frequently asked questions
The corpus contains 93 patent families in scope for this topic.
Cardiac Pacemakers Inc leads with 100 patent records among the top 100 ranked applicants, ahead of Pacesetter Inc at 56 and Medtronic Inc at 54.
The field is classified as Decline. Annual filing volume peaked around 2020 and has eased back since, indicating the core innovation wave has passed its apex.
The United States leads with 201 patent records, followed by Europe (EPO) at 104 and WIPO (PCT) at 52. Australia and Canada are the next largest national destinations.
A61N (Electrotherapy and radiation therapy) is the dominant branch by a large margin, reflecting that core pacing stimulation circuitry is the primary classification anchor. A61B (Diagnosis and surgery) is the main secondary branch.
The evidence identifies one active co-applicant pairing: Ceryx Medical Ltd and the University of Bath, with 10 jointly filed patent records. No other multi-party collaborations are recorded in the evidence.
Built on Patsnap Open Platform
This report’s underlying patent dataset — filings, assignees, technology clusters — is open for developers via MCP and REST API. Free to start, 10,000 credits, no credit card required.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.